Shares plunged 12% to $7.26 as Sionna Therapeutics confirmed what the market feared: the August trial failure wasn't a speed bump but a dead end. The company announced a 46% workforce reduction and plans to advance a proprietary two-drug cystic fibrosis combination into a new mid-stage trial expected to begin in early 2027, while formally abandoning its failed add-on program after it missed its primary endpoint. The restructuring crystallizes a company that traded above $49 just weeks ago into a stripped-down, single-bet biotech.
A Trial Failure Wiped Out 90% of the Stock — and Analysts Followed
Sionna's experimental drug failed to meaningfully reduce sweat chloride — a key measure of whether a cystic fibrosis treatment is working — showing a reduction of just -1.0 mmol/L versus placebo, sending shares down 92% on August 10.
Since then, BTIG, Guggenheim, Raymond James, and Wedbush have all downgraded the stock , with Wedbush slashing its price target from $53 to $5 and Stifel cutting from $55 to $7. Today's additional sell-off signals investors aren't reassured by the pivot.
The Company Is Betting the House on a Backup Plan
The new trial will test a two-drug combination in adults with cystic fibrosis for 28 days, with patients switching off the current standard treatment, Vertex's Trikafta. Management points to early-phase safety data and a post-hoc analysis showing biological activity of up to -8.6 mmol/L in a subset of the failed trial as justification. But post-hoc results — analyses done after the fact, cherry-picking subgroups — carry far less weight than the original trial's clear miss.
$268 Million in Cash Sounds Large, but the Clock Is Ticking
Sionna expects $6.4 million in restructuring charges against a cash pile of $268.3 million, and says cost cuts will extend its runway into the second half of 2029. At today's price, the company's net cash sits at roughly $5.75 per share — meaning the market values the entire pipeline at just ~$1.50 per share. That's a thin premium for a program that won't even generate proof-of-concept data until 2027 at the earliest.
Vertex Has Nothing to Worry About — Yet
Vertex Pharmaceuticals, the dominant cystic fibrosis player, remains a direct beneficiary of Sionna's continued setbacks.
The clinical failure effectively "removed a potential competitive threat" to Vertex , which controls the market Sionna is trying to crack. Until Sionna produces real proof its backup combo works, the stock is essentially a cash shell with an attached lottery ticket.